US 12,234,225 B2
IL-17 ligands and uses thereof
Paul R. Fatheree, San Francisco, CA (US); Martin S. Linsell, San Mateo, CA (US); John R. Jacobsen, San Mateo, CA (US); Wouter Van Der Linden, Menlo Park, CA (US); Timothy J. Church, San Mateo, CA (US); Claudio Aquino, Newark, CA (US); and Margot Paulick, San Carlos, CA (US)
Assigned to DICE ALPHA, INC., Indianapolis, IN (US)
Filed by DiCE Alpha, Inc., Indianapolis, IN (US)
Filed on Jul. 15, 2022, as Appl. No. 17/866,227.
Application 17/866,227 is a continuation of application No. 16/783,268, filed on Feb. 6, 2020, granted, now 11,447,468.
Claims priority of provisional application 62/901,249, filed on Sep. 16, 2019.
Claims priority of provisional application 62/801,870, filed on Feb. 6, 2019.
Prior Publication US 2023/0053746 A1, Feb. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 37/00 (2006.01); C07D 241/04 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 413/12 (2006.01); C07D 455/02 (2006.01); C07D 471/04 (2006.01)
CPC C07D 403/12 (2013.01) [A61P 37/00 (2018.01); C07D 241/04 (2013.01); C07D 401/12 (2013.01); C07D 403/14 (2013.01); C07D 413/12 (2013.01); C07D 455/02 (2013.01); C07D 471/04 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating psoriasis, psoriatic arthritis, or ankylosing spondylitis in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, solvate, or hydrate thereof wherein:
R1 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl —OR8 or —NR9R10;
R2 is alkyl, substituted alkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, fused cycloalkylaryl, substituted fused cycloalkylaryl, heteroaryl, or substituted heteroaryl;
each R3 is independently hydrogen, (C1-C7) alkyl, (C1-C7) substituted alkyl or —OR32;
m is 0, 1 or 2;
each R4 is independently hydrogen, (C1-C7) alkyl, or (C1-C7) substituted alkyl;
k is 1;
each R5 is hydrogen or —NR14C(O)R15;
R6 is hydrogen or alkyl; R7 is cycloheteroalkyl, substituted cycloheteroalkyl, —(CHR16)oR17 or —(CHR18)pR19 or R6 and R7 taken together with the nitrogen atom to which they are attached form piperazine, substituted piperazine, cycloheteroalkyl or substituted cycloheteroalkyl,

OG Complex Work Unit Chemistry
R8 is (C1-C7) alkyl, (C1-C7) substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
each R11 is hydrogen;
n is 1, 2, or 3;
o is 1, 2 or 3;
p is 1, 2 or 3;
each R16 is independently hydrogen, (C1-C7) alkyl or (C1-C7) substituted alkyl;
R17 is

OG Complex Work Unit Chemistry
each R18 is independently hydrogen, (C1-C7) alkyl or (C1-C7) substituted alkyl;
R19 is —NR27R28;
R27 and R28 together with the nitrogen atom to which they are attached form a cycloheteroalkyl or substituted cycloheteroalkyl ring or

OG Complex Work Unit Chemistry
 and
R9, R10, R14, R15, and R32 are independently hydrogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; or R9 and R10 together with atom to which they are attached form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring.